23andMe Holding Co. (NASDAQ:ME) Q1 2023 Earnings Conference Call August 8, 2022 4:30 PM ET

Company Participants

Wade Walke - Vice President, Investor Relations

Anne Wojcicki - Chief Executive Officer & Co-Founder

Steve Schoch - Chief Financial Officer

Kenneth Hillan - Chief Therapeutics Officer

Conference Call Participants

Tiago Fauth - Credit Suisse

David Lebowitz - Citi

Operator

Good morning, and welcome to 23andMe's Fiscal 2023 First Quarter Financial Results Conference Call. As a reminder this call is being recorded. At this time, all participants are listen-only mode. After the prepared remarks, there will be a question-and-answer session.

I would now like to hand the call over to Wade Walke, Vice President of Investor Relations to lead off the call. Thank you, please go ahead.

Wade Walke

Thank you. Before we begin, I encourage everyone to go to investors.23me.com to find the press release we issued earlier today reporting our financial results for the quarter. A replay of today's webcast will also be available on our website for a limited time within 24 hours after the event.

Please note that certain statements made during this call regarding matters that are not historical facts, including but not limited to management's outlook or predictions of future periods are forward-looking statements. These statements are based solely on information that is now available to us. We encourage you to review the section entitled forward-looking statements in our press release, which applies to this call. Also please refer to our SEC filings, which can be found on our website and the SEC's website for a discussion of numerous factors that may impact our future performance. We also discuss certain non-GAAP measures. Important information on our use of these measures and reconciliation to US GAAP may be found in our earnings release.

Joining us on our call today are Anne Wojcicki, our Chief Executive Officer and Co-Founder; and Steve Schoch, our Chief Financial Officer; Kenneth Hillan, our Chief Therapeutics Officer will join us for Q&A.

And now I'd like to turn the call over to Anne.

Anne Wojcicki

Thank you Wade. During our first fiscal quarter, we continued to make progress developing our genomic health service for customers and advancing our pipeline in the therapeutics business. In the consumer business, we continued to grow our customer base, which is now over 13 million genotype customers. In this last quarter, we added three new genetic risk reports for our 23andMe+ subscribers glaucoma, psoriasis and rosacea. This brings the number of health reports in our products to over 60. We are able to provide new insights to our customers on a regular basis thanks to the unmatched size of our consented database for genetic research.